The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Some but not all children will refuse to take medicine because of its taste, which can lead to substantial worsening of disease, antibiotic resistance, increased health care costs, and even death. The investigators are systematically assessing individual variation in the taste of liquid clindamycin among genotyped pediatric patients in the emergency room, to determine whether (1) genetic variation underlies differences in taste ratings of the antibiotic; (2) initial taste responses, genetics, or both predict likelihood of side effects and medication non-adherence.
Condition or disease
Medication AdherenceMedication Reaction
Taste plays an integral role in whether a child accepts a medicine. Some children will like the taste of a given medicine and complete the full course of treatment, whereas others will strongly reject its taste, suffer taste-modulated side effects, or both. This study will systematically measure initial palatability and reactions to the first dose of an antibiotic (clindamycin, liquid formulation) by pediatric patients who receive a diagnosis of skin and soft tissue infection (SSTI) in the emergency department (ED) and who are receiving clindamycin as part of their standard of care treatment. Saliva will be collected from all patients for GWAS. Taste response, tolerance of the medication, adherence and clinical outcomes will be assessed. Subjects will be followed to determine if they complete the 5-day medication regimen (adherence) and/or experience side effects (tolerability). Because medication-specific side effects have patient-specific variability, the investigators will determine whether the child's initial taste responses, genes, or both predict subsequent side effects and medication adherence.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
3 Years to 10 Years (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Pediatric patients who are prescribed clindamycin liquid for treatment of skin and soft tissue infection (SSTI) at the Children's Hospital of Philadelphia (CHOP) emergency department (ED).
Children age 3 to 10
Child being treated in Children's Hospital of Philadelphia Emergency Department
Diagnosis of a skin or soft tissue infection (SSTI)
Being prescribed clindamycin liquid for outpatient use
Parental/guardian permission (informed consent) and if appropriate, child assent
Parent age 18 or older, or a minor permitted by state law to consent for their own participation and for the participation of their child
Parent must have primary responsibility for the patient including biologic parents and adoptive parents (if legally allowed to consent to research)
Parent must be English speaking and able to understand study materials
Known exposure to (use of) clindamycin anytime in the child's past (assessed by review of CHOP prescribing record and parental report)